RT Journal Article
SR Electronic
T1 EGFRvIII – A Stable Target for Anti-EGFRvIII Therapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5343
OP 5348
VO 33
IS 12
A1 MATEUSZ BANASZCZYK
A1 EWELINA STOCZYNSKA-FIDELUS
A1 MARTA WINIECKA-KLIMEK
A1 MICHAL BIENKOWSKI
A1 WALDEMAR OCH
A1 PIOTR RIESKE
A1 SYLWESTER PIASKOWSKI
YR 2013
UL http://ar.iiarjournals.org/content/33/12/5343.abstract
AB Background: Epidermal growth factor receptor (EGFR) gene alterations play important roles in pathogenesis of glioblastoma. Antibodies against EGFRvIII have been recently developed. Their efficacy depends on numerous factors, including the co-existence of EGFRvIII with other genetic alterations, and especially with point mutations of EGFR. Materials and Methods: We examined 91 patients diagnosed with glioblastoma in order to determine the prevalence and mutual relationships between EGFR alterations. Real-time polymerase chain reaction (real-time PCR), fluorescent in situ hybridization (FISH), and sequencing were used to analyze prevalence of the amplification of EGFR gene, polysomy of chromosome 7, EGFRvIII mutation, and point mutations in exons 7-8 and 15 of EGFR. Results: We revealed that all these alterations can occur independently from each other. Nevertheless, the co-existence of EGFRvIII mutation and excessive copies of EGFR gene was observed in most cases (10/14). Similarly, the point mutations in exons 7-8 and 15 co-existed with an excessive number of EGFR copies in nearly all cases. Conclusion: EGFRvIII is a reliable and stable target for anti-EGFRvIII therapy.